<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cystic fibrosis-related diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cystic fibrosis-related diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cystic fibrosis-related diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shihab Hameed, BSc, MBBS, DCH, FRACP, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul D Robinson, MBChB, MRCPCH, FRACP, PhD, ATSF
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph I Wolfsdorf, MD, BCh
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Chmiel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H17626652">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cystic fibrosis (CF) is a life-limiting inherited single-gene disorder, and CF-related diabetes (CFRD) is a frequent complication for people with CF. CFRD is a distinct form of diabetes that is different from type 1 and type 2 diabetes mellitus [
         <a href="#rid1">
          1
         </a>
         ]. The primary cause is relative insulin deficiency. However, insulin resistance may also contribute to hyperglycemia, especially in association with acute respiratory exacerbations or systemic disease.
        </p>
        <p>
         Development of CFRD is associated with worse lung function, poorer nutritional status, and more chest infections. From the 1980s onward, the diagnosis of CFRD has been associated with early mortality [
         <a href="#rid2">
          2-5
         </a>
         ], particularly in females [
         <a href="#rid6">
          6
         </a>
         ]. Encouragingly, more recent data show a decline in the risk of death associated with CFRD [
         <a href="#rid7">
          7
         </a>
         ], which may be due to earlier diagnosis and insulin treatment [
         <a href="#rid2">
          2,3
         </a>
         ]. Insulin is a powerful anabolic agent, and insulin therapy improves nutritional status in people with CFRD [
         <a href="#rid8">
          8-10
         </a>
         ]. Insulin also reduces hyperglycemia and, thereby, may reduce lung infections [
         <a href="#rid8">
          8
         </a>
         ] and improve lung function. However, the addition of insulin treatment necessitates glucose monitoring and may add substantially to the burden of treatment for people with CF.
        </p>
        <p>
         The clinical presentation, surveillance, diagnosis, and treatment of CFRD are discussed in this topic review. CF-associated lung disease is discussed in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">
          "Cystic fibrosis: Management of advanced lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other aspects of CF care are also discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">
          "Cystic fibrosis: Assessment and management of pancreatic insufficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">
          "Cystic fibrosis: Hepatobiliary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H711144116">
         <span class="h1">
          EPIDEMIOLOGY AND NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD is a common complication of CF encountered among individuals school-aged and older [
         <a href="#rid11">
          11
         </a>
         ]. Significant hyperglycemia also has been reported in infants and young children [
         <a href="#rid12">
          12
         </a>
         ]; over time, this hyperglycemia may worsen and meet the diagnostic threshold for CFRD. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H711146319">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of CFRD increases with age, rising from approximately 20 percent at age 20 years to 40 percent by age 40 years, based on data from a North American CF patient registry in 2021  (
         <a class="graphic graphic_figure graphicRef140129" href="/z/d/graphic/140129.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid13">
          13,14
         </a>
         ]. Data from the European CF Patient Registry (2008 to 2015) show that rates rise from 0.8 percent in children &lt;10 years to 9.7 percent in those 10 to 19 years [
         <a href="#rid15">
          15
         </a>
         ]. The incidence is estimated to be between 4 to 9 percent per year in the Danish population [
         <a href="#rid16">
          16
         </a>
         ] and 2.7 cases per 100 individual-years [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711144387">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine function of the pancreas (including development of CFRD) is tightly correlated with exocrine (digestive) function of the pancreas; therefore, the strongest risk factors are markers for dysfunction of the exocrine (digestive) pancreas. The risk factors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         <strong>
          <em>
           CFTR
          </em>
         </strong>
         <strong>
          genotype
         </strong>
         – CFRD is more common in individuals with severe CF genotypes, including delta-F508 (pF508.del) homozygotes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pancreatic exocrine insufficiency
         </strong>
         – CFRD is much more common in those with pancreatic exocrine insufficiency, especially in those requiring pancreatic enzyme therapy. However, CFRD has been reported in up to 6 percent of patients with relatively normal pancreatic exocrine function (pancreatic-sufficient) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Risk for CFRD increases dramatically with age  (
         <a class="graphic graphic_figure graphicRef140129" href="/z/d/graphic/140129.html" rel="external">
          figure 1
         </a>
         ), as outlined above. (See
         <a class="local">
          'Epidemiology and natural history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female sex
         </strong>
         – The prevalence of CFRD is higher among females, at least after 30 years of age [
         <a href="#rid7">
          7
         </a>
         ]. Moreover, among patients with CFRD, women have reduced pulmonary function and survival compared with men and this may contribute toward the overall reduced lifespan observed for women with CF [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Mortality'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history of type 2 diabetes
         </strong>
         – A family history of type 2 diabetes increases the risk of CFRD [
         <a href="#rid18">
          18
         </a>
         ]. One mechanism for the observed genetic predisposition are variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602228&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrQkOS5GqcqXk5qofSEyQAe&amp;TOPIC_ID=14544" target="_blank">
          <i>
           TCF7L2
          </i>
         </a>
         gene, which is thought to be involved in beta cell proliferation [
         <a href="#rid19">
          19
         </a>
         ] and insulin secretion [
         <a href="#rid20">
          20
         </a>
         ] and is known to confer susceptibility to type 2 diabetes in the general population. Gene variants in
         <em>
          TCF7L2
         </em>
         among people with CF have been shown to increase their risk of diabetes approximately threefold [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CF-related liver disease
         </strong>
         – CF-related liver disease is also associated with increased rates of CFRD, possibly due to reduced insulin sensitivity and secretion or reflecting underlying systemic disease [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">
          "Cystic fibrosis: Hepatobiliary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H711144238">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H182820402">
         <span class="h2">
          Mechanisms of impaired glucose tolerance
         </span>
         <span class="headingEndMark">
          —
         </span>
         CF is caused by autosomal recessive mutations of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602421&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqr5%2FL8Flr%2BtdYHuYecJPEB&amp;TOPIC_ID=14544" target="_blank">
          <i>
           CFTR
          </i>
         </a>
         gene, which encodes the CFTR anion channel. This typically leads to multisystem disease including recurrent pulmonary infections and lung function decline, often with exocrine and endocrine pancreatic insufficiency resulting in CFRD. (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
         The pathophysiology of CFRD is complex. The primary defect is insulin deficiency, usually manifesting as a progressive loss of insulin secretory ability. Pancreatic exocrine dysfunction is a major feature in the development of diabetes in CF. However, not all people with CF develop diabetes and it is likely that there is a multifactorial process involving other factors such as inflammation, modifier genes, nutritional status, and changes to insulin sensitivity.
        </p>
        <p>
         A developmental abnormality may also contribute to the pathogenesis of CFRD. As an example, histopathology studies in very young children with CF (younger than four years of age) found no fibrosis or amyloidosis and normal islet number and mass, but low beta cell mass and reduced markers of beta cell proliferation, suggesting reduced capacity for beta cell formation [
         <a href="#rid22">
          22
         </a>
         ]. Islet interleukin-1 beta immunoreactivity may be an early contributing factor to this process [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Abnormal CFTR function within the islet is not thought to be a major factor in the pathogenesis of CFRD. Although CFTR ribonucleic acid (RNA) may be expressed in a small subpopulation of human beta cells, immunocytochemistry does not identify CFTR protein co-expression with insulin/glucagon/somatostatin positive cells and CFTR modulators do not increase insulin secretion in in vitro human islets [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Secondary mechanisms that contribute to diabetes in some individuals include liver dysfunction and therapies such as glucocorticoids (typically used for treating allergic bronchopulmonary aspergillosis) and immunosuppressant therapy following lung transplantation (eg,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H711144499">
         <span class="h2">
          Differences from other forms of diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a number of important differences between CFRD and type 1 and type 2 diabetes, which are summarized in the table  (
         <a class="graphic graphic_table graphicRef97525" href="/z/d/graphic/97525.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. Importantly, CFRD is only rarely associated with islet autoantibodies or human leukocyte antigen (HLA) class II types that are seen in type 1 diabetes mellitus [
         <a href="#rid25">
          25,26
         </a>
         ], although coexistent classic type 1 diabetes mellitus has been described in CF patients [
         <a href="#rid26">
          26,27
         </a>
         ]. Thus, the beta cell dysfunction seen in CFRD does not appear to have an autoimmune mechanism. Ketoacidosis rarely occurs in CFRD because most people with CF retain some insulin-secreting ability. Some overlap with type 2 diabetes mellitus is suggested by increased risk of CFRD in those with a family history of type 2 diabetes mellitus [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Several unique aspects of CF influence glucose metabolism and are not commonly encountered in other forms of diabetes. These include malnutrition, acute and chronic infection, malabsorption, abnormal intestinal transit time, liver dysfunction, increased work of breathing and elevated energy expenditure, and exposure to some CF treatments that can precipitate glucose intolerance such as glucocorticoids and immunosuppressants following lung/liver transplantation (eg,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1875731670">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD often presents insidiously with clinical decline in weight and lung function. This may precede the development of classic symptoms of diabetes such as polyuria and polydipsia by many years. Hence, screening programs such as annual oral glucose tolerance tests (OGTTs) are essential. (See
         <a class="local">
          'When to test'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2682764035">
         <span class="h2">
          Clinical stages of dysglycemia in cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory glucose abnormalities in CF depend on the stage of disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postprandial hyperglycemia
         </strong>
         – In the initial stages of dysglycemia in CF, the primary laboratory abnormality is postprandial hyperglycemia (ie, hyperglycemia in response to a glycemic load). This can be detected by sensitive measures such as continuous glucose monitoring (CGM). Another method of detecting these transient postprandial glucose excursions is to perform OGTTs with glucose levels collected every 30 minutes for two hours. These abnormalities reflect impaired first-phase insulin secretion [
         <a href="#rid28">
          28-30
         </a>
         ], with a small component of insulin resistance [
         <a href="#rid31">
          31
         </a>
         ]. The insulin resistance becomes more prominent during acute pulmonary exacerbations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CFRD diagnosed on elevated two-hour blood glucose values during OGTT (see
         <a class="local">
          'Diagnosis'
         </a>
         below). If the hyperglycemia is more pronounced, the patient may experience more prolonged postprandial glucose excursions, which meets the criteria for the diagnosis of CFRD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fasting hyperglycemia
         </strong>
         – Later stages of CFRD are characterized by fasting hyperglycemia. At this stage, hemoglobin A1c (HbA1c) may remain normal or may rise above the normal range; some individuals may develop classical symptoms of diabetes (polyuria and polydipsia) [
         <a href="#rid32">
          32
         </a>
         ]. These signs and symptoms reflect worsening insulin deficiency, which is often compounded by worsening insulin resistance, particularly during acute pulmonary exacerbations or in older individuals with CF [
         <a href="#rid33">
          33
         </a>
         ]. Chronic hyperglycemia may also impair insulin sensitivity by downregulation of GLUT4 transporter expression [
         <a href="#rid34">
          34,35
         </a>
         ], thus creating a vicious cycle of hyperglycemia resulting in insulin resistance and worsening hyperglycemia.
        </p>
        <p>
        </p>
        <p>
         Thus, postprandial hyperglycemia is the earliest and most sensitive marker of CFRD, and fasting hyperglycemia is a late phenomenon. HbA1c has relatively low sensitivity to detect CFRD but may become elevated in the later phases of the disease and is useful to monitor during treatment. (See
         <a class="local">
          'Diagnosis'
         </a>
         below and
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H711144811">
         <span class="h1">
          CLINICAL CONSEQUENCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a well-established body of evidence showing that hyperglycemia and insulin insufficiency have detrimental impacts on clinical outcomes in patients with CF. Deterioration in pulmonary function and nutrition status are often seen two to four years before formal diagnostic criteria for CFRD are met [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711146714">
         <span class="h2">
          Pulmonary function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies suggest detrimental effects of CFRD on both lung function and nutrition. A longitudinal study followed 152 individuals with CF and varying degrees of glucose intolerance or CFRD but without fasting hyperglycemia over four years [
         <a href="#rid17">
          17
         </a>
         ]. The highest rates of decline for forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and forced vital capacity were among the group with CFRD without fasting hyperglycemia. Participants in the lowest quartile for insulin production at baseline experienced the highest rates of pulmonary function decline over time, suggesting a relationship between insulin deficiency and clinical deterioration. Similarly, data from the Swedish registry of individuals with CF over age seven years described a greater rate of lung function decline in those with CFRD compared with those without CFRD [
         <a href="#rid37">
          37
         </a>
         ]. An association between early abnormalities in lung function (ventilation inhomogeneity, or unevenness of gas mixing, as measured by multiple-breath washout) and insulin secretory defects (as measured by oral glucose tolerance test [OGTT]) has been reported [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Laboratory studies suggest that elevated glucose levels on the airway surface promote bacterial growth and cause an exaggerated but less effective inflammatory response, providing a mechanistic explanation for the observed association between CFRD and pulmonary function. One study demonstrated that individuals with CFRD had elevated airway glucose levels, as measured by nasal glucose monitoring, compared with those without CFRD [
         <a href="#rid39">
          39
         </a>
         ]. Moreover, in vitro studies demonstrated that increased glucose exposure enhanced bacterial growth of
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         and
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         [
         <a href="#rid40">
          40
         </a>
         ], with significant changes occurring at far lower glucose levels than those documented in individuals with CF [
         <a href="#rid39">
          39
         </a>
         ]. A separate study in a mouse model of CF showed that airway hyperglycemia was associated with impaired ability to clear bacteria from the lung, despite enhanced recruitment of neutrophils to the airways [
         <a href="#rid41">
          41
         </a>
         ]. Several other effects of hyperglycemia have been reported: increased lactate generation and efflux, which acidify the airway surface liquid [
         <a href="#rid42">
          42
         </a>
         ]; a deleterious effect on transepithelial ion transport and epithelial repair functions [
         <a href="#rid43">
          43
         </a>
         ]; and proinflammatory changes with associated impairment of airway epithelial cell potassium channel function, which is important in mucus clearance [
         <a href="#rid44">
          44
         </a>
         ]. The airway glucose barrier is regulated by insulin and is dysfunctional in CF [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         People with CF who undergo lung transplantation have more complications and a higher mortality rate if they have preceding CFRD as compared with those without CFRD [
         <a href="#rid46">
          46,47
         </a>
         ]. It is hoped that with earlier and more effective treatment of diabetes, these differences in outcomes will diminish.
        </p>
        <p>
         Worsening hyperglycemia is associated with higher levels of the protein HMBG1 (high-mobility group box 1), which is involved in recognition of pathogens by toll-like receptors, cytokine production, and inflammation through receptors for advanced glycosylation end products [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711146720">
         <span class="h2">
          Nutritional status
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD is associated with poor nutritional status and, particularly, with a decline in nutritional status prior to its diagnosis. The nutritional impact of CFRD can be explained by the fact that insulin is a potent anabolic hormone that plays an important role in maintaining body weight and lean body mass. Insulin deficiency promotes a catabolic state with detrimental effects on nutritional outcomes. As an example, patients with CFRD (without fasting hyperglycemia) experienced a decline in body mass index (BMI) of 0.3±0.21 units over one year and this was reversed after the initiation of insulin therapy [
         <a href="#rid49">
          49
         </a>
         ]. Detrimental effects of CFRD also have been shown in milder CFRD categories. In a cohort of patients with CF and normal glucose tolerance (NGT; as defined by the OGTT), subclinical deficiencies of insulin secretion were detected by measuring the area under the curve for insulin secretion over the 120 minutes of the OGTT and greater impairment in insulin secretion was associated with the lowest BMI [
         <a href="#rid50">
          50
         </a>
         ]. Similarly, another study demonstrated that abnormalities in glucose homeostasis prior to the development of overt CFRD were associated with preceding declines in weight Z-score [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8304222">
         <span class="h2">
          Vascular complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD is associated with significant microvascular complications, including retinopathy [
         <a href="#rid52">
          52
         </a>
         ], neuropathy, and nephropathy. Historically, these complications have not been an important contributor to mortality for people with CFRD (unlike other forms of diabetes), but this may change with advances in treatment for pulmonary disease and related increases in longevity. Microvascular complications can develop after short diabetes duration [
         <a href="#rid53">
          53
         </a>
         ], and regular surveillance to identify these complications is recommended. (See
         <a class="local">
          'Monitoring for complications'
         </a>
         below.)
        </p>
        <p>
         The prevalence of microvascular complications is illustrated by a large cohort of patients with CFRD, in whom peripheral neuropathy and symptoms consistent with diabetic gastroenteropathy were each seen in 52 percent of patients [
         <a href="#rid54">
          54
         </a>
         ]. This frequency of neuropathy and diabetic gastroenteropathy was similar to that in patients with longstanding type 1 or type 2 diabetes. Among those with fasting hyperglycemia, 16 percent had retinopathy and 14 percent had nephropathy (indicated by moderately elevated albuminuria). These frequencies were somewhat lower than those for type 1 diabetes, but the complications tended to appear at lower levels of hemoglobin A1c (HbA1c) [
         <a href="#rid54">
          54,55
         </a>
         ]. Separate case reports have described severe retinopathy in individuals with CFRD and poor glycemic control, with proliferative retinopathy complicated by blindness despite laser therapy to the retina [
         <a href="#rid56">
          56
         </a>
         ]. Other reports from CF clinics have also described peripheral neuropathy, retinopathy, and nephropathy, which were generally associated with poor glycemic control and arose after 10 years of diabetes duration [
         <a href="#rid4">
          4,57,58
         </a>
         ]. Diabetic gastroenteropathy including gastroparesis also occurs in CFRD and may contribute to gastrointestinal symptoms. Antibiotic use also may contribute to the risk of peripheral neuropathy.
        </p>
        <p>
         Macrovascular disease may occur in CFRD but is uncommon. Myocardial disease has been found at postmortem examinations [
         <a href="#rid59">
          59
         </a>
         ], and symptomatic myocardial infarction has been described in a few case reports [
         <a href="#rid60">
          60,61
         </a>
         ]. Noninvasive measures of arterial stiffness, as a marker of large vessel disease, are higher in patients with CF and CFRD as compared with non-CF controls, without increases in blood pressure [
         <a href="#rid62">
          62
         </a>
         ], supporting the notion that CFRD increases the risk for cardiovascular disease. Of note, the advent of CF transmembrane conductance regulator (CFTR) modulator therapies has been associated with increased longevity and weight gain, sometimes leading to obesity and adverse cardiovascular risk factors; it is possible that these factors will increase the frequency of macrovascular disease among people with CF [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711146726">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD has been associated with increased mortality, especially in females, and this detrimental effect is greatly attenuated by early diagnosis and treatment. One report described the clinical course of 872 CF patients treated at a single center in Minnesota during three consecutive intervals: 1992 to 1997, 1998 to 2002, and 2003 to 2008 [
         <a href="#rid7">
          7
         </a>
         ]. Mortality in patients with and without CFRD significantly decreased over time. In females, the mortality rate halved from 6.9 to 3.2 deaths per 100 patient-years between the first and last study periods; in males, the mortality rate dropped from 6.5 to 3.8 deaths per 100 patient-years. Thus, early diagnosis and effective treatment of CFRD eliminated the sex gap in mortality and also narrowed the gap in mortality between those with and without CFRD. An analysis of patient data from 2008 to 2012 found that the mortality rate of individuals with CFRD was still 3.5 times greater than those without CFRD, suggesting that CFRD still contributes to mortality in older age groups despite aggressive CFRD surveillance and management [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711147053">
         <span class="h1">
          SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         As outlined above, CFRD is often clinically silent but increases morbidity and mortality and these effects can be attenuated by early diagnosis and treatment. Therefore, rigorous surveillance for the disorder is warranted.
        </p>
        <p class="headingAnchor" id="H711147146">
         <span class="h2">
          When to test
         </span>
         <span class="headingEndMark">
          —
         </span>
         All people with CF should undergo annual testing for CFRD beginning by 10 years of age, as outlined in multiple guidelines [
         <a href="#rid14">
          14,66-68
         </a>
         ]. Testing is particularly important for individuals with deteriorating nutritional or pulmonary status, which could signal the onset of CFRD. Routine surveillance testing should be performed during a period of baseline health (ie, not in the early stage of a pulmonary exacerbation) because illness can cause transient insulin resistance but may return to normal by the end of an exacerbation [
         <a href="#rid69">
          69
         </a>
         ]. The optimal screening test is an oral glucose tolerance test (OGTT), as discussed below. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         It is possible that routine surveillance testing will be extended to younger children in the future; some centers begin surveillance as early as six years of age because abnormal glucose tolerance at this age predicts early progression to CFRD [
         <a href="#rid70">
          70
         </a>
         ]. Abnormal glucose tolerance may develop even earlier; in one study performed across two CF centers, it was detected in almost 40 percent of children with CF between three months and five years of age [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         In addition to annual testing for all patients, testing is suggested in the following situations [
         <a href="#rid68">
          68
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute pulmonary exacerbations – During a significant acute exacerbation (eg, one that requires intravenous antibiotics or systemic glucocorticoids), screen by measuring fasting and postprandial blood glucose concentrations for the first 48 hours of treatment [
         <a href="#rid14">
          14
         </a>
         ]. Patients with abnormal results should have follow-up diagnostic testing with an OGTT after recovery from the exacerbation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with enteral tube feedings – Screen by measuring blood glucose concentrations midway through and immediately after a feed, at the time of enteral tube feeding initiation and monthly thereafter [
         <a href="#rid14">
          14,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy – Screen with OGTT prior to conception (if possible), at the end of both the first and second trimesters, and again 6 to 12 weeks after delivery [
         <a href="#rid68">
          68
         </a>
         ]. The diagnostic criteria for gestational diabetes are the same as for pregnant people without CF [
         <a href="#rid14">
          14,73
         </a>
         ]. Women with CF are at increased risk for gestational diabetes, but positive results of testing during pregnancy are considered to be gestational diabetes rather than CFRD. CFRD is diagnosed if the diabetes persists after delivery. Rigorous screening is important because CFRD can be detrimental to both the mother and the fetus.
        </p>
        <p>
        </p>
        <p>
         Interpretation of the results is discussed below. (See
         <a class="local">
          'Other diagnostic tests'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H711147139">
         <span class="h2">
          Selection of tests
         </span>
        </p>
        <p class="headingAnchor" id="H3463980823">
         <span class="h3">
          Oral glucose tolerance test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best test for diagnosis of CFRD is the OGTT. Interpretation of the results is outlined in the table  (
         <a class="graphic graphic_table graphicRef97528" href="/z/d/graphic/97528.html" rel="external">
          table 2
         </a>
         ) and discussed below. (See
         <a class="local">
          'Interpretation of the oral glucose tolerance test'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H848292542">
         <span class="h3">
          Other tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Not recommended
         </strong>
         – Tests not recommended for surveillance purposes (due to low sensitivity) include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemoglobin A1c (HbA1c)
         </strong>
         – If HbA1c is measured, a value ≥6.5 percent is consistent with a diagnosis of CFRD, as for other types of diabetes. This threshold has low sensitivity for detecting CFRD, with only 16 percent of CF patients having elevated HbA1c values at the time of CFRD diagnosis [
         <a href="#rid16">
          16
         </a>
         ]. The possibility of surveillance using HbA1c using a lower threshold of 5.8 percent has been proposed [
         <a href="#rid74">
          74
         </a>
         ], but this test still performs poorly for diagnosis compared with OGTT [
         <a href="#rid75">
          75
         </a>
         ]. Even lower thresholds (5.5 percent) may be appropriate, with sensitivity of 91 to 95 percent compared with the OGTT [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical symptoms
         </strong>
         – Symptoms are not a good method for surveillance for CFRD. In a population of pediatric CF patients in Toronto, only 2.7 percent were clinically recognized as having CFRD, but on OGTT testing of asymptomatic adolescents (aged 10 to 18 years), 17 percent were found to have impaired glucose tolerance (IGT) and 13 percent had CFRD (without fasting hyperglycemia) [
         <a href="#rid78">
          78
         </a>
         ]. In this cohort, an abnormal glucose tolerance was almost exclusively found in those with pancreatic insufficiency and severe (class 1 to 3) variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602421&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqr5%2FL8Flr%2BtdYHuYecJPEB&amp;TOPIC_ID=14544" target="_blank">
          <i>
           CFTR
          </i>
         </a>
         gene.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other
         </strong>
         – Glycosuria can be detected on simple urinalysis but is a very late feature of CFRD. Serial insulin levels can be used to quantify the degree of insulin deficiency [
         <a href="#rid17">
          17
         </a>
         ] but are mostly performed for research purposes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possibly useful
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Continuous glucose monitoring (CGM)
         </strong>
         – CGM is highly sensitive for identifying early stages of abnormal glucose tolerance, but its clinical utility as a diagnostic test has not been established [
         <a href="#rid14">
          14
         </a>
         ]. CGM is able to detect early abnormalities in glucose tolerance that may be missed by OGTT [
         <a href="#rid76">
          76,79-81
         </a>
         ], but diagnostic thresholds and clinical significance of mild abnormalities have not been established for the CF population. Glucose thresholds identifying risk of CFRD have been proposed but require further validation [
         <a href="#rid82">
          82
         </a>
         ]. In addition, the utility of treating CGM-detected abnormalities remains unclear, although one retrospective study suggested a beneficial effect of insulin on lung function and weight outcomes in adult patients with CGM evidence of hyperglycemia [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Possible utility of CGM as a diagnostic tool is suggested by numerous studies showing an association between elevated CGM glucose values and adverse clinical outcomes such as weight and lung function decline. Among patients with CF and normal OGTT results, those with higher maximum glucose values during CGM monitoring (≥11 mmol/L [200 mg/dL]) have worse pulmonary function and more
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         colonization compared with those with lower maximum glucose values (&lt;11 mmol/L) [
         <a href="#rid50">
          50
         </a>
         ]. In participants aged 10 to 18 years, positive correlations between CGM abnormalities and the rate of lung function decline have been reported [
         <a href="#rid84">
          84
         </a>
         ]. In children under six years of age, transient glucose excursions are associated with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection and pulmonary inflammation compared with no glucose excursions [
         <a href="#rid12">
          12
         </a>
         ]. Furthermore, elevated CGM values can predict worsening glycemia. In adults, CGM glucose levels &gt;200 mg/dL predicted the development of later CFRD [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If CGM is used, the optimal CGM metrics to monitor also remain unclear. Some examples of metrics explored are minimum daytime glucose; interquartile range; peak glucose; excursions &gt;140 mg/dL/day (&gt;7.8 mmol/L); percent of time within an acceptable range or, alternatively, time &gt;140 mg/dL (&gt;7.8 mmol/L); and standard deviation and mean amplitude of glycemic excursions [
         <a href="#rid84">
          84-86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although CGM has not been validated as a
         <strong>
          diagnostic
         </strong>
         tool for CFRD, its utility for monitoring glucose during insulin therapy for those with established CFRD is well established [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="local">
          'Glycemic targets and adjustment of insulin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17626658">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The oral glucose tolerance test (OGTT) is the test of choice for the diagnosis of CFRD and prediabetic stages of the disease. It is performed using a glucose load of 1.75 g/kg body weight (up to a maximum of 75 g). At a minimum, plasma glucose concentrations should be measured in the fasting state and both one and two hours after the glucose load. If possible, more frequent sampling is preferred (ie, taking samples at 0, 30, 60, 90, and 120 minutes) because this defines the rise in glucose levels in a more detailed way and captures the peak glucose that may otherwise be missed [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         In addition, testing for islet autoantibodies should be performed for selected people with CFRD [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial diagnosis of CFRD at age &lt;10 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presentation with diabetic ketoacidosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 1 diabetes or other autoimmune disease in a first-degree relative
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal history of other autoimmune disease
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H711146819">
         <span class="h2">
          Interpretation of the oral glucose tolerance test
         </span>
         <span class="headingEndMark">
          —
         </span>
         CFRD represents one end of a spectrum of abnormalities of glucose tolerance in CF. This spectrum is reflected in the diagnostic categories used for interpretation of the OGTT  (
         <a class="graphic graphic_table graphicRef97528" href="/z/d/graphic/97528.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal glucose tolerance (NGT)
         </strong>
         – Fasting plasma glucose &lt;100 mg/dL (5.6 mmol/L)
         <strong>
          and
         </strong>
         two-hour plasma glucose &lt;140 mg/dL (7.8 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired fasting glucose (IFG)
         </strong>
         – Fasting plasma glucose 100 to 125 mg/dL (5.6 to 7 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because the clinical significance of IFG in people with CF is unclear, it is not generally used as a diagnostic category in the CFRD spectrum [
         <a href="#rid87">
          87,88
         </a>
         ]. However, it is a common finding: In a registry study from Germany and Austria, IFG was present in 25 percent of individuals with CF at 14 years of age and was more common than was impaired glucose tolerance (IGT) at all ages [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prediabetic categories
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indeterminate glycemia (INDET)
         </strong>
         – One-hour plasma glucose peak ≥200 mg/dL (11.1 mmol/L), but normal two-hour plasma glucose and fasting plasma glucose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This category is unique to CF. It is included in the CFRD classification system because blood glucose levels in people with CF are often elevated at the 30-, 60-, or 90-minute timepoints, then return to normal by the two-hour timepoint [
         <a href="#rid51">
          51,89,90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Impaired glucose tolerance (IGT)
         </strong>
         – Two-hour plasma glucose 140 to 200 mg/dL (7.8 to 11.1 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both INDET and IGT are important risk factors for progression to overt diabetes [
         <a href="#rid32">
          32
         </a>
         ]. In one study, participants classified as INDET on OGTT were 10 times more likely to develop CFRD over the five-year study period compared with those classified as having IFG or NGT [
         <a href="#rid91">
          91
         </a>
         ]. The clinical significance of these categories will become more apparent as comprehensive data become available, describing the natural history of CFRD and its pulmonary, nutritional, and microvascular complications. (See
         <a class="local">
          'Clinical consequences'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CFRD
         </strong>
         – Two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L). If this result is found on the initial OGTT, repeat testing is recommended to confirm the diagnosis, unless there are symptoms of polyuria and polydipsia [
         <a href="#rid14">
          14,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Historically, CFRD was subcategorized by the absence or presence of fasting hyperglycemia (fasting plasma glucose ≥126 mg/dL [7.0 mmol/L]). Fasting hyperglycemia usually represents a more advanced stage of disease and is associated with microvascular complications [
         <a href="#rid68">
          68
         </a>
         ]. However, because treatment is beneficial for patients with and without fasting hyperglycemia, this distinction is no longer made routinely [
         <a href="#rid14">
          14,49,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While there is a general trend from INDET to frank CFRD with fasting hyperglycemia, fluctuation between severity stages may occur. As an example, in a four-year study, glucose tolerance deteriorated in 22 percent of participants and improved in 18 percent [
         <a href="#rid17">
          17
         </a>
         ]. In another prospective study, 58 percent of those with IGT subsequently had normal OGTT results [
         <a href="#rid16">
          16
         </a>
         ]. These changes in diagnostic categories may be due to acute changes in clinical status (eg, pulmonary exacerbations), which affect insulin sensitivity [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gestational diabetes
         </strong>
         – For individuals who are pregnant, the diagnostic criteria for gestational diabetes are the same as for pregnant people without CF [
         <a href="#rid14">
          14,73
         </a>
         ]. CFRD is diagnosed if the diabetes persists after delivery. (See
         <a class="medical medical_review" href="/z/d/html/6797.html" rel="external">
          "Gestational diabetes mellitus: Screening, diagnosis, and prevention", section on 'Validation of the 75-gram GTT'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8305013">
         <span class="h2">
          Other diagnostic tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         As an alternative to diagnosing CFRD based on results of an OGTT, other tests may qualify for the diagnosis under certain circumstances [
         <a href="#rid68">
          68
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CFRD may be diagnosed during a period of stable baseline health if a patient meets other standard criteria for diagnosis of diabetes on two occasions (hemoglobin A1c [HbA1c] ≥6.5 percent, fasting plasma glucose ≥126 mg/dL [7 mmol/L]) or classical symptoms of diabetes in the presence of a random plasma glucose concentration ≥200 mg/dL (11.1 mmol/L). However, it should be noted that HbA1c and fasting plasma glucose have low sensitivity for detecting CFRD, so normal values do not exclude the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients on enteral tube feedings, CFRD may be diagnosed if mid- or post-feeding plasma glucose levels are ≥200 mg/dL (11.1 mmol/L) on two separate days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In CF patients with acute illness (eg, those hospitalized with a pulmonary exacerbation), the diagnosis of CFRD can be made if fasting plasma glucose is ≥126 mg/dL (7 mmol/L) or postprandial plasma glucose is ≥200 mg/dL persisting for more than 48 hours. (See
         <a class="local">
          'Selection of tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17626691">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2302345581">
         <span class="h2">
          Diet and drinks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, most patients with CF, including those with CFRD, require a high-calorie diet. Hence, caloric restriction should not be routinely recommended, except in the case of significant obesity or abnormally rapid weight gain. Excessive weight gain may become increasingly relevant in the era of CF transmembrane conductance regulator (CFTR) modulator therapy because this therapy often promotes weight gain (which may be either beneficial or excessive).
        </p>
        <p>
         Nutritional management alone, without insulin treatment, is not recommended for CFRD [
         <a href="#rid14">
          14
         </a>
         ]. Insulin doses can be distributed to reflect carbohydrate consumption, and carbohydrate counting can be useful in determining the premeal dose.
        </p>
        <p>
         Other than these considerations for glycemic load, dietary goals are identical to those for all people with CF. This includes personalization to that individual's specific nutritional goals, accounting for changes that may be needed in those treated with highly effective CFTR modulator therapy.
        </p>
        <p>
         For those not on highly effective CFTR modulator therapy, nutritional goals typically include [
         <a href="#rid24">
          24,68,93
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liberal intake of total energy (calories) – Recommended intakes are generally 120 to 150 percent or more of the estimated energy requirement for age and sex, with a goal of maintaining body mass index (BMI) ≥50
         <sup>
          th
         </sup>
         percentile for age and sex. Caloric targets may need adjusting for those on CFTR modulator therapy. For comparison, recommended intakes of energy and key nutrients for children
         <strong>
          without
         </strong>
         CF are summarized in the table  (
         <a class="graphic graphic_table graphicRef78274" href="/z/d/graphic/78274.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liberal intake of fat – eg, 40 percent of total energy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate proportion of carbohydrates – eg, 45 to 50 percent of total energy (ideally with low glycemic load for patients with CFRD or abnormal glucose tolerance).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High intake of protein – eg, 1.5 to 2 times the dietary reference intake for age, including in patients with nephropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High intake of salt – Sodium intake is unrestricted because people with CF have increased requirements.
        </p>
        <p>
        </p>
        <p>
         These dietary goals differ from those for patients with type 1 or type 2 diabetes mellitus, for whom dietary recommendations restrict total energy, fat, protein, and sodium intakes. Nutritional management of patients with CF is discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8303547">
         <span class="h2">
          Insulin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend treatment with insulin therapy for all patients with CFRD. The insulin dose, regimen, and glycemic targets differ from those used for type 1 and type 2 diabetes, as outlined below.
        </p>
        <p class="headingAnchor" id="H1854277118">
         <span class="h3">
          Indications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Established CFRD
         </strong>
         – We recommend insulin therapy for CFRD, with or without fasting hyperglycemia, consistent with multiple guidelines [
         <a href="#rid14">
          14,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For people with established CFRD, insulin therapy clearly has beneficial effects on nutrition and probably improves pulmonary function and survival. In a randomized trial, adult patients with CFRD without fasting hyperglycemia gained 0.39±0.21 BMI units during one year of insulin therapy, which reversed the BMI decline that they had experienced during the year prior to treatment [
         <a href="#rid49">
          49
         </a>
         ] (see
         <a class="local">
          'Nutritional status'
         </a>
         above). Among the insulin-treated participants, there was a trend toward slower rate of decline in pulmonary function compared with the rate of decline prior to treatment; insulin-treated participants also tended to have a slower overall decline in pulmonary function compared with those treated with placebo, but neither of these findings reached statistical significance [
         <a href="#rid49">
          49
         </a>
         ]. Multiple small observational studies with one to three years of follow-up confirm improvements in BMI after initiation of insulin therapy and also document improvements in pulmonary function, as measured by forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ), or reductions in acute pulmonary infections [
         <a href="#rid9">
          9,94-97
         </a>
         ]. As an example, among 42 young adults with CFRD, insulin therapy slowed the annual rate of decline for FEV
         <sub>
          1
         </sub>
         , delaying the decline by an average of 34 months [
         <a href="#rid9">
          9
         </a>
         ]. CFRD-associated mortality was described in an observational study from a single center and documented progressively lower mortality rates over a 20-year period, which narrowed the gap in mortality between CF patients with and without diabetes and eliminated the sex gap in mortality [
         <a href="#rid7">
          7
         </a>
         ]. Because the center progressively improved protocols for early identification and treatment of CFRD, this study provides indirect evidence that insulin therapy reduces CFRD-associated mortality. (See
         <a class="local">
          'Mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indeterminate glycemia (INDET) or impaired glucose tolerance (IGT)
         </strong>
         – For people with oral glucose tolerance test (OGTT) results in these prediabetic categories (see
         <a class="local">
          'Interpretation of the oral glucose tolerance test'
         </a>
         above), there is insufficient evidence to support the use of insulin treatment as standard care. Additionally, some practices will initiate insulin for selected patients when a decline in BMI or FEV
         <sub>
          1
         </sub>
         is first noted, but there is inadequate evidence to recommend this practice, although additional research is pending (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01100892&amp;token=Ste%2FJ%2B0Zk8%2BGCpKsBOssVXs7REdxnziGg6IyMw%2BTV0KDbRivO5wpXLhD8Vgeu4G0Ix2PRl6D%2Bn5QFcV7Wl7EPA%3D%3D&amp;TOPIC_ID=14544" target="_blank">
          NCT01100892
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3834159101">
         <span class="h3">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         General principles for CFRD management are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give as much insulin as can be safely tolerated to eliminate the catabolic effects of CFRD
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain hemoglobin A1c (HbA1c) as low as possible
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HbA1c target is &lt;7 percent and ideally in the lower part of the normal range (&lt;5.5 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An increase in HbA1c above the baseline level (prior to insulin therapy) suggests that insufficient insulin is being given
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Test blood glucose preprandially (fasting) and postprandially (approximately one to two hours after eating)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If preprandial hypoglycemia is detected, reduce basal insulin dose
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If postprandial hyperglycemia is detected, increase basal insulin dose or add prandial insulin to maximize benefits for the lung
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1799881975">
         <span class="h3">
          Insulin dose and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         During periods of clinical stability, patients with CFRD typically require insulin doses of 0.5 to 0.8 units/kg/day [
         <a href="#rid14">
          14
         </a>
         ]. The dose should be adjusted up to the maximum that can be safely tolerated to eliminate the catabolic effects of CFRD without causing frequent or severe hypoglycemia. Considerably higher insulin doses may be required during acute pulmonary exacerbations or other conditions of systemic illness.
        </p>
        <p>
        </p>
        <p>
         Several approaches to insulin dosing may be used, depending on the patient's characteristics and response  (
         <a class="graphic graphic_table graphicRef97532 graphicRef61880" href="/z/d/graphic/97532.html" rel="external">
          table 4A-B
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal insulin
         </strong>
         – Early in the course of disease, a single daily basal insulin injection usually can achieve desired outcomes and has lower treatment burden than regimens that include multiple daily insulin injections. In our practice, we initiate insulin therapy with a long-acting insulin analog (such as
         <a class="drug drug_general" data-topicid="9022" href="/z/d/drug information/9022.html" rel="external">
          insulin detemir
         </a>
         or glargine in the morning) at 0.1 units/kg. We then increase the dose by increments of 0.1 unit/kg, aiming for postprandial blood glucose &lt;140 mg/dL (7.8 mmol/L) without hypoglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For those on overnight feeds, insulin is given in the evening, using a long-acting insulin (eg, detemir or glargine) in combination with a rapid-acting or
         <a class="drug drug_general" data-topicid="9030" href="/z/d/drug information/9030.html" rel="external">
          regular insulin
         </a>
         . An alternative is NPH (neutral protamine hagedorn; also known as isophane insulin) given alone, but it has a very variable pharmacodynamic response in comparison with detemir and glargine [
         <a href="#rid98">
          98
         </a>
         ]. Blood glucose should be checked at four to five hours after commencement and at the end of feeds to titrate the dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prandial insulin
         </strong>
         – If fasting hyperglycemia develops and postprandial hyperglycemia persists, we add a prandial bolus prior to meals while reducing the dose of basal insulin. The prandial bolus is a rapid-acting insulin, with a starting dose of 0.5 to 1 unit per 15 g carbohydrate (15 g of carbohydrate may be referred to as a carbohydrate exchange).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with marked dysglycemia at diagnosis, basal and prandial insulin can be initiated simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Correction
         <strong>
          doses
         </strong>
         – In addition to giving prandial and/or basal doses of insulin as described above, episodes of hyperglycemia are treated by administering correction doses of insulin, calculated to lower blood glucose to a target of 90 mg/dL (5 mmol/L), using a correction factor of 1 unit insulin to lower blood glucose by approximately 55 to 110 mg/dL (3 to 6 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insulin pump
         </strong>
         – Insulin pumps are increasingly used for the management of CFRD, as they are for other forms of diabetes [
         <a href="#rid95">
          95,99
         </a>
         ]. The approach to determining basal and prandial insulin doses is similar to that described above, although the total daily insulin dose may be somewhat lower for pump users.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Insulin pump therapy has evolved to "advanced hybrid closed-loop" therapy. These systems automatically adjust insulin delivery according to algorithms to prevent hypoglycemia and correct hyperglycemia, based on sensor glucose values from a continuous glucose monitor (CGM). It is not known if these systems will work in people with CF in the same manner as for those with type 1 diabetes, but preliminary results are encouraging [
         <a href="#rid100">
          100,101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/123060.html" rel="external">
          "Continuous subcutaneous insulin infusion (insulin pump)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special situations
         </strong>
         – During hospitalizations, the starting dose for basal insulin is generally 0.2 units/kg. During treatment with glucocorticoids, the insulin requirement typically increases considerably. Most patients also require prandial insulin during intercurrent infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For surgical procedures such as port insertions, insulin usually can be withheld without risk of significant hyperglycemia. CFRD is rarely associated with ketoacidosis, so there is a low risk of developing ketosis during short periods without insulin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8303882">
         <span class="h3">
          Glycemic targets and adjustment of insulin
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Self-monitoring of blood glucose
         </strong>
         – People with CFRD on insulin therapy should either use a CGM device or perform self-monitoring of blood glucose (SMBG; via "fingerstick") at least three times a day, as is recommended for all individuals with diabetes [
         <a href="#rid14">
          14,68
         </a>
         ]. In selected patients unwilling or unable to perform this frequent SMBG, less frequent but staggered SMBG monitoring to provide an overall picture of glucose control may be suitable.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preprandial blood glucose
         </strong>
         – SMBG should be performed prior to meals (fasting), especially during periods of illness or changes in insulin dosing, and routinely during periods of baseline health. Target fasting blood glucose is 70 to 144 mg/dL (4 to 8 mmol/L) when on basal insulin, as outlined in the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Guidelines [
         <a href="#rid14">
          14
         </a>
         ]. If preprandial hypoglycemia is detected, the basal insulin dose should be decreased. Preprandial testing is important because spontaneous hypoglycemia is common among individuals with CF, even in the absence of insulin therapy [
         <a href="#rid102">
          102,103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         CF patients are prone to postprandial hypoglycemia (reactive hypoglycemia), due to delayed and disordered insulin secretion [
         <a href="#rid14">
          14
         </a>
         ]. They tend to have reduced glucagon response to hypoglycemia but normal catecholamine response [
         <a href="#rid68">
          68
         </a>
         ]. Patients on insulin therapy should be educated about the risks of hypoglycemia and its management, including the use of glucagon.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Postprandial blood glucose
         </strong>
         – SMBG also should be performed one to two hours after meals. If hyperglycemia is detected, the basal insulin dose should be increased or a prandial dose of rapid-acting insulin should be added; the goal is to maintain postprandial blood glucose in the normal range (&lt;180 mg/dL [10 mmol/L]). More frequent SMBG may be needed after changes in insulin dose or during acute illness. Postprandial testing is important to maximize the benefit of insulin therapy on pulmonary function, and the optimal timepoint for testing may be one hour after meals. This was suggested by a study of young adolescents with CF in good baseline health, in which the one-hour glucose excursion on OGTT was negatively associated with lung function; this was not the case for the two-hour stimulated value, which is typically used to make the diagnosis of diabetes [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HbA1c
         </strong>
         – Although HbA1c is not recommended as a diagnostic test for CFRD, it is helpful in monitoring treatment and should be measured every three months in patients on insulin treatment [
         <a href="#rid14">
          14,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The goals and glycemic targets for CFRD differ from those used for type 1 diabetes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with CFRD, maintaining an HbA1c treatment goal of ≤7 percent (53 mmol/mol) has been recommended to reduce the risk of microvascular complications [
         <a href="#rid14">
          14
         </a>
         ]. However, if achievable without significant hypoglycemia, we suggest trying to maintain HbA1c as low as possible, ideally in the lower part of the normal range (eg, HbA1c &lt;5.5 percent). While formal evidence to outline the benefits of doing this is lacking, there is emerging evidence that glucose control during pulmonary exacerbations is associated with subsequent recovery of FEV
         <sub>
          1
         </sub>
         [
         <a href="#rid105">
          105
         </a>
         ]. For this reason, we believe that this strategy may be beneficial in reducing pulmonary exacerbations and preserving lung function, but further studies are required. In one study, good CFRD control (defined in this study as HbA1c &lt;7 percent) was not associated with fewer pulmonary infections, but it is possible that a benefit would have been found if a more stringent HbA1c threshold had been used [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         At diagnosis, patients with CFRD often have HbA1c in the nondiabetic range (&lt;6 percent) or in the borderline dysglycemic range (6 to 6.5 percent). HbA1c is correlated with average glucose in CFRD [
         <a href="#rid107">
          107
         </a>
         ]. If the HbA1c increases above the baseline level (measured prior to insulin therapy), the insulin dose usually should be increased.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CGM
         </strong>
         – CGM provides frequent measurements of glycemia and insight about insulin needs and responsiveness. Many people with diabetes prefer CGM over fingersticks, and CGM is particularly useful for those whose CFRD is difficult to manage through standard approaches, such as those with poor growth despite insulin therapy. CGM has been validated in people with CF, and its utility is comparable to individuals with diabetes who do not have CF [
         <a href="#rid108">
          108-110
         </a>
         ]. Consensus CGM glycemic targets for other forms of diabetes are available [
         <a href="#rid111">
          111
         </a>
         ]. In general, CGM targets for people with CFRD are similar to those with other forms of diabetes, as suggested by the ISPAD [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">
          "Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Continuous glucose monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Changes in interstitial glucose levels lag behind changes in plasma glucose, often by several minutes [
         <a href="#rid112">
          112
         </a>
         ]. For this reason, fingerstick levels should be checked if there are symptoms of hypoglycemia or other clinical reasons to suspect the CGM result may not reflect the blood glucose value.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8304734">
         <span class="h2">
          Monitoring for complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CFRD should undergo routine monitoring for complications, as outlined in the table  (
         <a class="graphic graphic_table graphicRef97533" href="/z/d/graphic/97533.html" rel="external">
          table 5
         </a>
         ) and detailed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microvascular complications
         </strong>
         – CFRD leads to chronic microvascular complications, including retinopathy, nephropathy, and neuropathy. The frequency of these complications depends on disease duration and glycemic control and appears to be similar to that for type 1 diabetes, although, in CFRD, they tend to appear at lower levels of HbA1c. (See
         <a class="local">
          'Vascular complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Annual monitoring for microvascular complications is recommended, beginning five years after the diagnosis of CFRD or at the time that CFRD with fasting hyperglycemia is first diagnosed (whichever is earlier) [
         <a href="#rid14">
          14,68
         </a>
         ]. Monitoring procedures are the same as for patients with type 1 diabetes and consist of dilated eye examination for retinopathy, urine albumin:creatinine ratio (spot specimen), and sensory examination of the feet for peripheral neuropathy. (See
         <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">
          "Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Vascular complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension
         </strong>
         – Measurement of blood pressure is recommended at all routine visits [
         <a href="#rid68">
          68
         </a>
         ]. Hypertension is a concern in CFRD, primarily because it may contribute to nephropathy. If hypertension is present, it should be treated as recommended for other people with diabetes, usually with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). (See
         <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">
          "Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyslipidemia
         </strong>
         – Annual testing with a lipid panel is recommended for people with CFRD and pancreatic sufficiency or for those with risk factors for cardiovascular disease (post-transplantation, obesity, or family history of early cardiovascular disease) [
         <a href="#rid68">
          68
         </a>
         ]. Hyperlipidemia and macrovascular disease are rare in patients with CF, except in those with pancreatic exocrine sufficiency (which is particularly uncommon among patients with CFRD). However, with improvements in nutritional status, dyslipidemia may become more common.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1854277404">
         <span class="h2">
          Oral hypoglycemic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral antidiabetic agents are not currently recommended in CFRD [
         <a href="#rid14">
          14
         </a>
         ]. Only a few such agents have been evaluated in clinical trials and were largely unsuccessful [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
         Most of the trials were of
         <a class="drug drug_general" data-topicid="9604" href="/z/d/drug information/9604.html" rel="external">
          repaglinide
         </a>
         , a meglitinide that promotes beta cell insulin secretion [
         <a href="#rid49">
          49,114
         </a>
         ]. In a randomized trial, treatment with repaglinide yielded transient improvement in IGT during the first six months of therapy, but the benefit was not sustained at 12 months, whereas insulin therapy had an ongoing positive effect on weight gain [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9005" href="/z/d/drug information/9005.html" rel="external">
          Exenatide
         </a>
         (a glucose-like peptide-1 agonist) was evaluated in a small crossover trial in six participants with IGT but not CFRD, which reported some improvement in postprandial hyperglycemia that was probably due to delayed gastric emptying rather than improvements in insulin secretion [
         <a href="#rid115">
          115
         </a>
         ]. A small randomized trial of
         <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">
          sitagliptin
         </a>
         found no benefit on glucose tolerance or measures of beta cell glucose sensitivity [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1156498612">
         <span class="h2">
          Effect of CFTR modulator treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         A new class of drugs known as CF transmembrane conductance regulator (CFTR) modulators target the underlying defect in CFTR function [
         <a href="#rid117">
          117
         </a>
         ]. Emerging evidence suggests that these drugs can have beneficial effects on a wide range of CF outcomes. Their effect on CFRD has not been fully established, but several studies suggest possible benefits [
         <a href="#rid118">
          118-120
         </a>
         ]. In one study of adults with CF and at least one F508del mutation, with or without CFRD, initiation of
         <a class="drug drug_general" data-topicid="122968" href="/z/d/drug information/122968.html" rel="external">
          elexacaftor-tezacaftor-ivacaftor
         </a>
         was associated with improvements in glycemic control (reduced time above CGM target range 70 to 180 mg/dL, but no change in time below range) [
         <a href="#rid121">
          121
         </a>
         ]. A separate study described reduced insulin requirements with
         <a class="drug drug_general" data-topicid="17144" href="/z/d/drug information/17144.html" rel="external">
          ivacaftor
         </a>
         treatment in adult patients with ivacaftor-sensitive
         <em>
          CFTR
         </em>
         mutations [
         <a href="#rid122">
          122
         </a>
         ]. In other studies, treatment with
         <a class="drug drug_general" data-topicid="102504" href="/z/d/drug information/102504.html" rel="external">
          lumacaftor-ivacaftor
         </a>
         (a CFTR modulator that has relatively modest effects on other CF outcomes) did not improve insulin secretion or glycemia [
         <a href="#rid123">
          123-125
         </a>
         ]. Further data on glycemic outcomes following use of combination therapies are awaited.
        </p>
        <p>
         Details of CFTR modulator therapy, including selection based on genotype and efficacy for other CF-related outcomes, are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1238597052">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109226.html" rel="external">
          "Society guideline links: Cystic fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8302199">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and natural history
         </strong>
         – Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis (CF) among individuals school-aged and older  (
         <a class="graphic graphic_figure graphicRef140129" href="/z/d/graphic/140129.html" rel="external">
          figure 1
         </a>
         ). Its prevalence increases markedly with age, rising to more than 40 percent after 30 years of age. Risk factors for developing CFRD include severe genotype (eg, F508del homozygotes), pancreatic insufficiency, and female sex. (See
         <a class="local">
          'Epidemiology and natural history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The primary abnormality predisposing to CFRD is slowly progressive insulin deficiency. Acute pulmonary exacerbations tend to further impair glucose tolerance and may trigger CFRD because inflammatory cytokines and catecholamines promote insulin resistance. (See
         <a class="local">
          'Differences from other forms of diabetes mellitus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical consequences
         </strong>
         – CFRD is associated with clinically important declines in pulmonary function and nutritional status, as well as with increased mortality. These effects may be attenuated or reversed by treatment with insulin. (See
         <a class="local">
          'Clinical consequences'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance (screening)
         </strong>
         – All patients with CF should undergo annual testing for CFRD, beginning by 10 years of age. The most appropriate test is an oral glucose tolerance test (OGTT), performed during a period of baseline health. A normal hemoglobin A1c (HbA1c) should not be used to exclude CFRD. In addition to annual testing described above, monitoring of blood glucose is suggested during acute pulmonary exacerbations and for patients on enteral tube feedings. (See
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Interpretation of the OGTT is outlined in the table  (
         <a class="graphic graphic_table graphicRef97528" href="/z/d/graphic/97528.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Interpretation of the oral glucose tolerance test'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insulin treatment
         </strong>
         – We recommend treatment with insulin for all patients with CFRD rather than dietary management or no treatment (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Insulin therapy has beneficial effects on nutrition and probably improves pulmonary function and survival. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glycemic targets and dose adjustment
         </strong>
         – For CFRD, the insulin dose, regimen, and glycemic targets differ from those used for type 1 and type 2 diabetes. General principles for CFRD management are to give as much insulin as can be safely tolerated to eliminate the catabolic effects of CFRD, maintain HbA1c &lt;7 percent (and, ideally, lower), and minimize postprandial hyperglycemia while avoiding episodes of hypoglycemia. The insulin regimen varies depending on the patient's characteristics and response  (
         <a class="graphic graphic_table graphicRef97532" href="/z/d/graphic/97532.html" rel="external">
          table 4A
         </a>
         ). (See
         <a class="local">
          'Insulin dose and administration'
         </a>
         above and
         <a class="local">
          'Glycemic targets and adjustment of insulin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – Monitoring during insulin therapy includes self-monitoring of blood glucose (SMBG) via fingerstick or continuous glucose monitoring (CGM) and laboratory measurement of HbA1c every three months  (
         <a class="graphic graphic_table graphicRef97533" href="/z/d/graphic/97533.html" rel="external">
          table 5
         </a>
         ). In addition, patients with CFRD should undergo annual surveillance for microvascular complications, beginning five years after diagnosis of CFRD. (See
         <a class="local">
          'Glycemic targets and adjustment of insulin'
         </a>
         above and
         <a class="local">
          'Monitoring for complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Future directions
         </strong>
         – Technologies for the management of diabetes including CGM, insulin pumps, and automated closed-loop pump systems are revolutionizing the management of other forms of diabetes and are now being introduced to manage CFRD. (See
         <a class="local">
          'Insulin therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CF transmembrane conductance regulator (CFTR) modulator drugs have important benefits on pulmonary outcomes and other markers of CF-related disease. They are likely to alter the emergence of glycemic abnormalities in CF, and their effects of the management of CFRD will be studied in the coming years. (See
         <a class="local">
          'Effect of CFTR modulator treatments'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2740812899">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kim Donaghue, MB, BS, PhD, FRACP, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998; 133:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008; 152:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenecker J, Höfler R, Steinkamp G, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res 2001; 6:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sims EJ, Green MW, Mehta A. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care 2005; 28:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32:1626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan K, Israel KL, Miller H, et al. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 2008; 76:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001; 90:515.
          </a>
         </li>
         <li class="breakAll">
          Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prentice BJ, Ooi CY, Strachan RE, et al. Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J Cyst Fibros 2019; 18:869.
          </a>
         </li>
         <li class="breakAll">
          2021 Cystic Fibrosis Foundation Patient Registry. Available at: https://www.cff.org/medical-professionals/patient-registry (Accessed on November 21, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ode KL, Ballman M, Battezzati A, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2022; 23:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olesen HV, Drevinek P, Gulmans VA, et al. Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al. J Cyst Fibros 2020; 19:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanng S, Hansen A, Thorsteinsson B, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995; 311:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackman SM, Hsu S, Ritter SE, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009; 52:1858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008; 283:8723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegner L, Hussain MS, Pilgaard K, et al. Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 2008; 93:4013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayas MS, Hughan KS, Javaid R, et al. 1788-P: Islet Function in Youth with Cystic Fibrosis with and without Liver Disease. Diabetes 2020; 69:1788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogdani M, Blackman SM, Ridaura C, et al. Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes. Sci Rep 2017; 7:17231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull RL, Gibson RL, McNamara S, et al. Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure. Diabetes Care 2018; 41:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009; 10 Suppl 12:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanng S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993; 82:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konrad K, Kapellen T, Lilienthal E, et al. Does β-Cell Autoimmunity Play a Role in Cystic Fibrosis-Related Diabetes? Analysis Based on the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Care 2016; 39:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atlas AB, Finegold DN, Becker D, et al. Diabetic ketoacidosis in cystic fibrosis. Am J Dis Child 1992; 146:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milner AD. Blood glucose and serum insulin levels in children with cystic fibrosis. Arch Dis Child 1969; 44:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilmshurst EG, Soeldner JS, Holsclaw DS, et al. Endogenous and exogenous insulin responses in patients with cystic fibrosis. Pediatrics 1975; 55:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh S, Gudipaty L, De Leon DD, et al. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes 2017; 66:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanng S, Thorsteinsson B, Røder ME, et al. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf) 1994; 41:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmid K, Fink K, Holl RW, et al. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros 2014; 13:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colomba J, Boudreau V, Lehoux-Dubois C, et al. The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. J Cyst Fibros 2019; 18:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klip A, Tsakiridis T, Marette A, Ortiz PA. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. FASEB J 1994; 8:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab 2007; 5:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granados A, Chan CL, Ode KL, et al. Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis. J Cyst Fibros 2019; 18 Suppl 2:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002; 33:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colombo C, Alicandro G, Gambazza S, et al. Ventilation inhomogeneity is associated with OGTT-derived insulin secretory defects in cystic fibrosis. Pediatr Pulmonol 2019; 54:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnett JP, Gray MA, Tarran R, et al. Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. PLoS One 2013; 8:e76283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt WR, Zughaier SM, Guentert DE, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306:L43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnett JP, Kalsi KK, Sobotta M, et al. Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H(+) secretion. Sci Rep 2016; 6:37955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilodeau C, Bardou O, Maillé É, et al. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J Cyst Fibros 2016; 15:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bengtson CD, Kim MD, Anabtawi A, et al. Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance. Eur Respir J 2021; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina SA, Moriarty HK, Infield DT, et al. Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner. Am J Physiol Lung Cell Mol Physiol 2017; 312:L688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradbury RA, Shirkhedkar D, Glanville AR, Campbell LV. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study. Intern Med J 2009; 39:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mainbourg S, Philit F, Touzet S, et al. Cystic fibrosis-related diabetes before lung transplantation is associated with lower survival but does not affect long-term renal function. Pediatr Pulmonol 2019; 54:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montanini L, Cirillo F, Smerieri A, et al. HMGB1 Is Increased by CFTR Loss of Function, Is Lowered by Insulin, and Increases In Vivo at Onset of CFRD. J Clin Endocrinol Metab 2016; 101:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran A, Pekow P, Grover P, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009; 32:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leclercq A, Gauthier B, Rosner V, et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros 2014; 13:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hameed S, Morton JR, Jaffé A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010; 33:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts R, Speight L, Lee J, et al. Retinal screening of patients with cystic fibrosis-related diabetes in Wales -- a real eye opener. J Cyst Fibros 2015; 14:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aulich J, Cho YH, Januszewski AS, et al. Associations between circulating inflammatory markers, diabetes type and complications in youth. Pediatr Diabetes 2019; 20:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen HU, Lanng S, Pressler T, et al. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006; 29:2660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan MM, Denning CR. Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics 1989; 84:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanng S, Thorsteinsson B, Lund-Andersen C, et al. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr 1994; 83:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Berg JM, Morton AM, Kok SW, et al. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008; 7:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zebrak J, Skuza B, Pogorzelski A, et al. Partial CFTR genotyping and characterisation of cystic fibrosis patients with myocardial fibrosis and necrosis. Clin Genet 2000; 57:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onady GM, Farinet CL. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm Med 2006; 6:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aratari MT, Venuta F, De Giacomo T, et al. Lung transplantation for cystic fibrosis: ten years of experience. Transplant Proc 2008; 40:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull JH, Garrod R, Ho TB, et al. Increased augmentation index in patients with cystic fibrosis. Eur Respir J 2009; 34:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. J Clin Transl Endocrinol 2021; 26:100276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 2022; 21:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis C, Blackman SM, Nelson A, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 2015; 191:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilschanski M, Braegger CP, Colombo C, et al. Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2016; 63:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33:2697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Widger J, Oliver MR, O'Connell M, et al. Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis. PLoS One 2012; 7:e44844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ode KL, Frohnert B, Laguna T, et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010; 11:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi Y, Norris AW, Wang K, et al. Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis. Am J Respir Crit Care Med 2016; 194:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzenberg SJ, Hempstead SE, McDonald CM, et al. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. J Cyst Fibros 2016; 15:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgess JC, Bridges N, Banya W, et al. HbA1c as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros 2016; 15:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boudreau V, Coriati A, Desjardins K, Rabasa-Lhoret R. Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros 2016; 15:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CL, Ode KL, Granados A, et al. Continuous glucose monitoring in cystic fibrosis - A practical guide. J Cyst Fibros 2019; 18 Suppl 2:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boudreau V, Reynaud Q, Bonhoure A, et al. Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis-Related Diabetes in Adults. Can J Diabetes 2019; 43:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon MP, Wilson DC, Corey M, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr 2003; 142:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mainguy C, Bellon G, Delaup V, et al. Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard? J Pediatr Endocrinol Metab 2017; 30:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zorrón Mei Hsia Pu M, Gonçalves AC, Minnicucci WJ, et al. Continuous glucose monitoring to evaluate glycaemic abnormalities in cystic fibrosis. Arch Dis Child 2018; 103:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clemente León M, Bilbao Gassó L, Moreno-Galdó A, et al. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients. Endocrinol Diabetes Nutr (Engl Ed) 2018; 65:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor-Cousar JL, Janssen JS, Wilson A, et al. Glucose &gt;200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. J Diabetes Res 2016; 2016:1527932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost F, Dyce P, Nazareth D, et al. Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros 2018; 17:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CL, Vigers T, Pyle L, et al. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibros 2018; 17:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brugha R, Wright M, Nolan S, et al. Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis. J Cyst Fibros 2018; 17:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon SL, Vigers T, Campbell K, et al. Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis. Pediatr Diabetes 2018; 19:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheuing N, Holl RW, Dockter G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One 2013; 8:e81545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frohnert BI, Ode KL, Moran A, et al. Impaired fasting glucose in cystic fibrosis. Diabetes Care 2010; 33:2660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004; 21:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh S, Putt ME, Forde KA, et al. Elevation of one hour plasma glucose during oral glucose tolerance testing. Pediatr Pulmonol 2015; 50:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004; 3:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mozzillo E, Franzese A, Valerio G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009; 10:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009; 8:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafii M, Chapman K, Stewart C, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr 2005; 81:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes DR, Sheehan JP, Ulchaker MM, Rebar JM. Management dilemmas in the individual with cystic fibrosis and diabetes. J Am Diet Assoc 1994; 94:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ode KL, Chan CL, Granados A, et al. Cystic fibrosis related diabetes: Medical management. J Cyst Fibros 2019; 18 Suppl 2:S10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherwood JS, Jafri RZ, Balliro CA, et al. Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study. J Cyst Fibros 2020; 19:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scully KJ, Palani G, Zheng H, et al. The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes. Diabetes Technol Ther 2022; 24:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battezzati A, Battezzati PM, Costantini D, et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol 2007; 156:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001; 24:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodsky J, Dougherty S, Makani R, et al. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011; 34:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okoniewski W, Hughan KS, Weiner GA, et al. Glycemic control and FEV1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes. J Cyst Fibros 2020; 19:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belle-van Meerkerk G, de Valk HW, Stam-Slob MC, et al. Cystic Fibrosis-Related Diabetes with strict glycaemic control is not associated with frequent intravenous antibiotics use for pulmonary infections. Diabetes Res Clin Pract 2016; 116:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CL, Hope E, Thurston J, et al. Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis. Diabetes Care 2018; 41:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefferies C, Solomon M, Perlman K, et al. Continuous glucose monitoring in adolescents with cystic fibrosis. J Pediatr 2005; 147:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordan SM, Hindmarsh P, Hill NR, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009; 32:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobson L, Sheldon CD, Hattersley AT. Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis. Diabetes Care 2003; 26:1940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaharieva DP, Turksoy K, McGaugh SM, et al. Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology During Aerobic Exercise in Adults Living with Type 1 Diabetes. Diabetes Technol Ther 2019; 21:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onady GM, Stolfi A. Drug treatments for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2020; 10:CD004730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballmann M, Hubert D, Assael BM, et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geyer MC, Sullivan T, Tai A, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial. Diabetes Obes Metab 2019; 21:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly A, Sheikh S, Stefanovski D, et al. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance. J Clin Endocrinol Metab 2021; 106:2617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentzsch M, Mall MA. Ion Channel Modulators in Cystic Fibrosis. Chest 2018; 154:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris AW. Is Cystic Fibrosis-related Diabetes Reversible? New Data on CFTR Potentiation and Insulin Secretion. Am J Respir Crit Care Med 2019; 199:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly A, De Leon DD, Sheikh S, et al. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy. Am J Respir Crit Care Med 2019; 199:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinack C, Ernst M, Beuschlein F, et al. Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis. J Cyst Fibros 2023; 22:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scully KJ, Marchetti P, Sawicki GS, et al. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros 2022; 21:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaines H, Jones KR, Lim J, et al. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications 2021; 35:107845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moheet A, Beisang D, Zhang L, et al. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros 2021; 20:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li A, Vigers T, Pyle L, et al. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros 2019; 18:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomassen JC, Mueller MI, Alejandre Alcazar MA, et al. Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients. J Cyst Fibros 2018; 17:271.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14544 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672504" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Abnormal glucose metabolism in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16123480" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18346512" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11549516" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3346774" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diabetes mellitus associated with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983304" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19542209" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7981562" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17960051" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Long-term effect of insulin treatment in cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11430710" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11430710" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31036487" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31036487" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36537525" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31680042" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7549632" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Glucose tolerance in patients with cystic fibrosis: five year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10988101" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19585101" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18216022" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18611970" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : 1788-P: Islet Function in Youth with Cystic Fibrosis with and without Liver Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29222447" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29437698" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Islet Interleukin-1βImmunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute toβ-Cell Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19754617" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Management of cystic fibrosis-related diabetes in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8097419" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diabetes mellitus in cystic fibrosis: genetic and immunological markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27271187" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Doesβ-Cell Autoimmunity Play a Role in Cystic Fibrosis-Related Diabetes? Analysis Based on the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1456258" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Diabetic ketoacidosis in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4891523" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Blood glucose and serum insulin levels in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1110865" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Endogenous and exogenous insulin responses in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27495225" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Reducedβ-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923827" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23809507" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30711385" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8299889" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403369" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The GLUT4 glucose transporter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31679726" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12001283" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Predictors of deterioration of lung function in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30575293" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Ventilation inhomogeneity is associated with OGTT-derived insulin secretory defects in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16844431" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24124542" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24097557" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27897253" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H(+) secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25920899" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732330" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28213469" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19220548" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an 'orphan' area? A retrospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30854801" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cystic fibrosis-related diabetes before lung transplantation is associated with lower survival but does not affect long-term renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26760176" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : HMGB1 Is Increased by CFTR Loss of Function, Is Lowered by Insulin, and Increases In Vivo at Onset of CFRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19592632" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359972" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910502" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25224328" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Retinal screening of patients with cystic fibrosis-related diabetes in Wales -- a real eye opener.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31464058" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Associations between circulating inflammatory markers, diabetes type and complications in youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17322485" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Microvascular complications in cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130201" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2780126" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Diabetic microangiopathy in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193478" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18619927" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733236" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Partial CFTR genotyping and characterisation of cystic fibrosis patients with myocardial fibrosis and necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16681861" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : An adult cystic fibrosis patient presenting with persistent dyspnea: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675113" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lung transplantation for cystic fibrosis: ten years of experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19608591" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Increased augmentation index in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34868883" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Obesity in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34862121" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25479583" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27472479" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27068495" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21115772" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23028642" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20202149" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Oral glucose tolerance testing in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27447840" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27599607" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20190296" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25869326" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : HbA1c as a screening tool for cystic fibrosis related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26905501" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31679725" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Continuous glucose monitoring in cystic fibrosis - A practical guide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30713090" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis-Related Diabetes in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12584532" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Glucose intolerance in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27977404" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29378680" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Continuous glucose monitoring to evaluate glycaemic abnormalities in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29137964" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999822" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Glucose&gt;200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29885744" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29580828" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29329721" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30022572" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24324701" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Diabetes in cystic fibrosis: multicenter screening results based on current guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21115768" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Impaired fasting glucose in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15209760" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Conventional measures underestimate glycaemia in cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10499886" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26087115" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Elevation of one hour plasma glucose during oral glucose tolerance testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15698938" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical importance of cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18442507" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207231" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19162566" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Use of the insulin pump in treat cystic fibrosis related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699230" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8270758" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Management dilemmas in the individual with cystic fibrosis and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15161770" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31679720" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cystic fibrosis related diabetes: Medical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31420176" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35020476" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17322497" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Spontaneous hypoglycemia in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11574430" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21228248" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31980357" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Glycemic control and FEV1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27321340" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Cystic Fibrosis-Related Diabetes with strict glycaemic control is not associated with frequent intravenous antibiotics use for pulmonary infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29674323" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16182684" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Continuous glucose monitoring in adolescents with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279304" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766139" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31177185" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31059282" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology During Aerobic Exercise in Adults Living with Type 1 Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075159" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Drug treatments for managing cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29199116" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30259623" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34406395" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29750923" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Ion Channel Modulators in Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30192635" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Is Cystic Fibrosis-related Diabetes Reversible? New Data on CFTR Potentiation and Insulin Secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30130412" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36669960" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34531155" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33558149" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32917547" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30104123" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29249670" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
